Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors Ernest NadalBartomeu MassutiEnriqueta Felip Review 06 February 2019 Pages: 341 - 352
The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma Boyang ChangTao HuangPeihong Wu Original Article Open access 01 December 2018 Pages: 353 - 363
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions Wanghong HuZhenguo ZiFang Wei Original Article 06 December 2018 Pages: 365 - 377
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model Diana LlopizMarta RuizPablo Sarobe Original Article 13 December 2018 Pages: 379 - 393
Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ Lin LinPatricia RaymanC. Marcela Diaz-Montero Original Article 14 December 2018 Pages: 395 - 405
Identification and characterization of an alternative cancer-derived PD-L1 splice variant Nadia B. HassounahVenkat S. MalladiEsra A. Akbay Original Article 18 December 2018 Pages: 407 - 420
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression Kathleen M. MahoneySachet A. ShuklaGordon J. Freeman Original Article Open access 18 December 2018 Pages: 421 - 432
Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer Rui ZhouJingwen ZhangWangjun Liao Original Article Open access 19 December 2018 Pages: 433 - 442
Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater Min Hwan KimMi JangHye Jin Choi Original Article 02 January 2019 Pages: 443 - 454
The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice Hussein SultanTakumi KumaiEsteban Celis Original Article 02 January 2019 Pages: 455 - 466
CD73 expression in normal and pathological human hepatobiliopancreatic tissues Amedeo SciarraInês MonteiroLaurence de Leval Original Article 04 January 2019 Pages: 467 - 478
Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance Anna MalyshkinaElisabeth Littwitz-SalomonUlf Dittmer Original Article 11 January 2019 Pages: 479 - 488
STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes Morten Nørgaard AndersenAnders EtzerodtHolger J. Møller Original Article 14 January 2019 Pages: 489 - 502
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial Charlotte M. HuijtsSinéad M. Lougheedfor the Dutch WIN-O Consortium Original Article Open access 17 January 2019 Pages: 503 - 515
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer Alberto A. ChiapporiCharles C. WilliamsScott J. Antonia Clinical Trial Report Open access 27 December 2018 Pages: 517 - 527
Correction to: CD73 expression in normal and pathological human hepatobiliopancreatic tissues Amedeo SciarraInês MonteiroLaurence de Leval Correction 05 February 2019 Pages: 529 - 529
